{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:47:05Z","timestamp":1780634825369,"version":"3.54.1"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec018\">\n<jats:title>Background<\/jats:title>\n<jats:p>The presence of hypertension and various acute or chronic complications may affect the renin-angiotensin-aldosterone system (RAAS) in patients with type 2 diabetes mellitus (T2DM), which plays a crucial role in the regulation of glucose metabolism. However, the quantitative distribution of the RAAS components in relation to the progression of T2DM and the treatment of hyperglycemia and hypertension, as well as their association with different stages of complications and glucose metabolism, has not been well studied.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec019\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We enrolled a total of 151 patients with T2DM and essential hypertension, 40 patients with T2DM and normotension, and 46 healthy controls in the study. They were categorized into subgroups based on criteria for diabetic complications. Statistical analyses, including Spearman rank correlation and multiple linear regression, were conducted to assess the relationship between RAAS components and glucose metabolism indexes such as HbA1c, FBG, CP, HOMA-\u03b2, HOMA-IR, and UACR.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec020\">\n<jats:title>Results<\/jats:title>\n<jats:p>The results revealed significant differences in AII, ALD, REN, and ARR levels across various complication subgroups. Notably, the concentrations of ALD and REN exhibited a consistent trend, while ARR showed an opposite trend to the REN concentration. More than 60% of hypertensive patients were treated with ACEI\/ARBs and calcium channel blockers, while 29.8% of the patients were prescribed \u03b2-blockers, resulting in decreased REN and increased ARR levels. All T2DM patients received antidiabetic treatment, among which 95 (49.7%) took SGLT-2is, 40 (20.9%) took GLP-1RAs injection and 55(28.8%) took DPP-4is. The subsequent analysis revealed that SGLT-2is, GLP-1RAs, DPP-4is and other glucose-lowering agents had no statistically significant effect on the RAAS system (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). The correlation matrix analysis indicated positive associations between ALD, REN, CP, and HOMA-IR. Furthermore, the REN levels were negatively correlated with UACR in the hypertensive group and positively correlated with HbA1c and FBG levels in the normotensive group. Multiple linear regression analysis demonstrated that ALD levels increased with higher levels of CP and HOMA-IR, independently of the RAAS system, anti-RAAS treatment and antidiabetic therapy. REN levels decreased with increasing UACR and \u03b2-blocker usage in the hypertensive group, while they increased with higher levels of HbA1c, FBG, and HOMA-IR in the normotensive group, independently of the RAAS system and antidiabetic therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec021\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The activation status of the RAAS system varied among T2DM patients with different complications, highlighting the need for clinical differentiation. ALD was positively associated with insulin resistance and glucose metabolism impairment, while REN exhibited negative correlations with urinary microalbumin and \u03b2-blocker usage, and positive correlations with hyperglycemia and insulin resistance. Blocking the RAAS system holds promise for improving insulin sensitivity and \u03b2-cell function, and potentially reversing abnormal glucose tolerance or ameliorating glucose metabolism disorders.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0316049","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T17:33:42Z","timestamp":1742405622000},"page":"e0316049","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Renin-angiotensin-aldosterone system variations in type 2 diabetes mellitus patients with different complications and treatments: Implications for glucose metabolism"],"prefix":"10.1371","volume":"20","author":[{"given":"Ningning","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erjun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6911-0177","authenticated-orcid":true,"given":"Baohong","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"pone.0316049.ref001","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"H Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"pone.0316049.ref002","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cmet.2017.01.004","article-title":"Reducing VEGF-B signaling ameliorates renal lipotoxicity and protects against diabetic kidney disease","volume":"25","author":"A Falkevall","year":"2017","journal-title":"Cell Metab"},{"issue":"24","key":"pone.0316049.ref003","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1001\/jama.2017.7596","article-title":"Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013","volume":"317","author":"L Wang","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"pone.0316049.ref004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2337\/dbi17-0013","article-title":"Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication","volume":"67","author":"C Hu","year":"2018","journal-title":"Diabetes"},{"issue":"12","key":"pone.0316049.ref005","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa0908292","article-title":"Prevalence of diabetes among men and women in China","volume":"362","author":"W Yang","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0316049.ref006","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2013.168118","article-title":"Prevalence and control of diabetes in Chinese adults","volume":"310","author":"Y Xu","year":"2013","journal-title":"JAMA"},{"key":"pone.0316049.ref007","doi-asserted-by":"crossref","first-page":"m997","DOI":"10.1136\/bmj.m997","article-title":"Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study","volume":"369","author":"Y Li","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"pone.0316049.ref008","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/inthealth\/ihad047","article-title":"Prevalence of hypertension among type 2 diabetes mellitus patients in China: a systematic review and meta-analysis","volume":"16","author":"X Zhang","year":"2024","journal-title":"Int Health"},{"issue":"17","key":"pone.0316049.ref009","doi-asserted-by":"crossref","first-page":"e009890","DOI":"10.1161\/JAHA.118.009890","article-title":"Renin-angiotensin-aldosterone system, glucose metabolism and incident type 2 diabetes mellitus: MESA","volume":"7","author":"JJ Joseph","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"pone.0316049.ref010","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/jch.13517","article-title":"The association of calcium channel blockers with \u03b2-cell function in type 2 diabetic patients: a cross-sectional study","volume":"21","author":"D Zhao","year":"2019","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"pone.0316049.ref011","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/1753-0407.12644","article-title":"International diabetes federation 2017","volume":"10","author":"AM Carracher","year":"2018","journal-title":"J Diabetes"},{"issue":"1","key":"pone.0316049.ref012","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11906-012-0323-2","article-title":"The renin angiotensin aldosterone system and insulin resistance in humans","volume":"15","author":"PC Underwood","year":"2013","journal-title":"Curr Hypertens Rep"},{"issue":"11","key":"pone.0316049.ref013","first-page":"1090","article-title":"A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy","volume":"19","author":"Z Rahimi","year":"2014","journal-title":"J Res Med Sci"},{"issue":"4","key":"pone.0316049.ref014","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1210\/jc.2016-1002","article-title":"Aldosterone, renin, and diabetes mellitus in African Americans: the Jackson heart study","volume":"101","author":"JJ Joseph","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"pone.0316049.ref015","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.tips.2011.07.006","article-title":"The renin-angiotensin-aldosterone system and glucose homeostasis","volume":"32","author":"JM Luther","year":"2011","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"pone.0316049.ref016","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/s-0029-1246189","article-title":"Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn\u2019s Registry","volume":"42","author":"M Reincke","year":"2010","journal-title":"Horm Metab Res"},{"issue":"5","key":"pone.0316049.ref017","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"PA James","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"pone.0316049.ref018","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.dsx.2017.12.005","article-title":"Renin angiotensin-aldosterone system (RAAS) blockers usage among type II diabetes mellitus patients \u2013 a retrospective study","volume":"12","author":"YP Ng","year":"2018","journal-title":"Diabetes Metab Syndr"},{"issue":"3","key":"pone.0316049.ref019","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/0004563217728964","article-title":"Associations between glycaemic control and activation of the renin-angiotensin-aldosterone system in participants with type 2 diabetes mellitus and hypertension","volume":"55","author":"TP Griffin","year":"2018","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"pone.0316049.ref020","doi-asserted-by":"crossref","first-page":"F830-9","DOI":"10.1152\/ajprenal.00266.2007","article-title":"Activation of a local renin angiotensin system in podocytes by glucose","volume":"294","author":"RV Durvasula","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"pone.0316049.ref021","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/01.HYP.3.1.87","article-title":"Low plasma renin activity in normotensive patients with diabetes mellitus: relationship to neuropathy","volume":"3","author":"Jr Fernandez-Cruz A","year":"1981","journal-title":"Hypertension"},{"issue":"10","key":"pone.0316049.ref022","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/jcm7100360","article-title":"Higher screening aldosterone to renin ratio in primary aldosteronism patients with diabetes mellitus","volume":"7","author":"C-H Chang","year":"2018","journal-title":"J Clin Med"},{"issue":"1","key":"pone.0316049.ref023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjhyper.2003.08.015","article-title":"Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients","volume":"17","author":"MH Alderman","year":"2004","journal-title":"Am J Hypertens"},{"issue":"1","key":"pone.0316049.ref024","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s11906-014-0506-0","article-title":"Plasma renin testing to guide antihypertensive therapy","volume":"17","author":"AJ Viera","year":"2015","journal-title":"Curr Hypertens Rep"},{"issue":"7","key":"pone.0316049.ref025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"KG Alberti","year":"1998","journal-title":"Diabet Med"},{"issue":"5","key":"pone.0316049.ref026","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"JW Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"pone.0316049.ref027","first-page":"199","article-title":"Plasma renin activity in diabetic patients","volume":"74","author":"D Koev","year":"1979","journal-title":"Endokrinologie"},{"issue":"1","key":"pone.0316049.ref028","first-page":"P3-13","article-title":"The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology","volume":"93","author":"G Wolf","year":"2003","journal-title":"Nephron Physiol"},{"issue":"9","key":"pone.0316049.ref029","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1681\/ASN.2007020149","article-title":"Angiotensin II-induced reactive oxygen species and the kidney","volume":"18","author":"A Sachse","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"pone.0316049.ref030","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.12669\/pjms.38.8.5523","article-title":"Changes of plasma aldosterone and angiotensin II levels in patients with ischemic cardiomyopathy combined with Type-2 diabetes mellitus and their clinical significance","volume":"38","author":"R Tang","year":"2022","journal-title":"Pak J Med Sci"},{"issue":"1","key":"pone.0316049.ref031","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12933-016-0485-3","article-title":"Blood pressure control in type 2 diabetic patients","volume":"16","author":"A Grossman","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"pone.0316049.ref032","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/HJH.0000000000000775","article-title":"A cross-sectional study of the effects of \u03b2-blocker therapy on the interpretation of the aldosterone\/renin ratio: can dosing regimen predict effect?","volume":"34","author":"TP Griffin","year":"2016","journal-title":"J Hypertens"},{"issue":"3","key":"pone.0316049.ref033","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/cen.12882","article-title":"\u03b2-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension","volume":"84","author":"GA Browne","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"pone.0316049.ref034","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/01.HYP.0000038478.59760.41","article-title":"Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism","volume":"40","author":"P Mulatero","year":"2002","journal-title":"Hypertension"},{"issue":"3","key":"pone.0316049.ref035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3317\/jraas.2001.022","article-title":"Diagnosis and management of primary aldosteronism","volume":"2","author":"M Stowasser","year":"2001","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"pone.0316049.ref036","doi-asserted-by":"crossref","first-page":"738848","DOI":"10.3389\/fendo.2021.738848","article-title":"Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system","volume":"12","author":"S Puglisi","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"pone.0316049.ref037","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12902-020-00656-8","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study","volume":"20","author":"T Sawamura","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"pone.0316049.ref038","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/a-0794-7026","article-title":"Effect of sodium glucose Co-transporter-2 inhibition on the aldosterone\/renin ratio in type 2 diabetes mellitus","volume":"51","author":"TP Griffin","year":"2019","journal-title":"Horm Metab Res"},{"issue":"1","key":"pone.0316049.ref039","doi-asserted-by":"crossref","first-page":"19603","DOI":"10.1038\/s41598-022-24280-9","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis","volume":"12","author":"W Manosroi","year":"2022","journal-title":"Sci Rep"},{"issue":"Supplement_1","key":"pone.0316049.ref040","doi-asserted-by":"crossref","DOI":"10.2337\/db18-1196-P","article-title":"Effects of SGLT2 inhibitors on renin-aldosterone system for one month and six months in type 2 diabetes","volume":"67","author":"I MORI","year":"2018","journal-title":"Diabetes"},{"key":"pone.0316049.ref041","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1475-2840-12-160","article-title":"Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes","volume":"12","author":"K Miyagawa","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"pone.0316049.ref042","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.steroids.2014.08.016","article-title":"Effects of aldosterone on insulin sensitivity and secretion","volume":"91","author":"JM Luther","year":"2014","journal-title":"Steroids"},{"issue":"6","key":"pone.0316049.ref043","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1161\/HYPERTENSIONAHA.111.180521","article-title":"Plasma aldosterone levels and development of insulin resistance: prospective study in a general population","volume":"58","author":"E Kumagai","year":"2011","journal-title":"Hypertension"},{"issue":"5","key":"pone.0316049.ref044","first-page":"448","article-title":"Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis","volume":"17","author":"M Al-Mallah","year":"2010","journal-title":"Cardiol J"},{"issue":"16","key":"pone.0316049.ref045","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of valsartan on the incidence of diabetes and cardiovascular events","volume":"362","author":"Group NAVIGATOR Study","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0316049.ref046","first-page":"2526","article-title":"Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney","volume":"118","author":"I Toma","year":"2008","journal-title":"J Clin Invest"},{"issue":"5","key":"pone.0316049.ref047","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1681\/ASN.2008070740","article-title":"Activation of the succinate receptor GPR91 in macula densa cells causes renin release","volume":"20","author":"SL Vargas","year":"2009","journal-title":"J Am Soc Nephrol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T17:35:28Z","timestamp":1742405728000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316049"}},"subtitle":[],"editor":[{"given":"Nalini","family":"Govender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0316049","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]}}}